Slide 1: Fourth Quarter 2022 Earnings
Fourth Quarter 2022 Earnings F e b r u a r y 2 8 , 2 0 2 3
Slide 2: Forward-looking statements
These presentations contain forward-looking statements within the meaning of federal securities laws, including, among others, statements about our expectations, plans, strategies or prospects. We generally use the words “may,” “will,” “expect,” “believe,” “anticipate,” “plan,” “estimate,” “project,
Slide 3: Fourth Quarter 2022 Financial Highlights
Consolidated Revenue $617 million Fourth Quarter 2022 Financial Highlights(1) (1) Non-GAAP measures shown have been adjusted for certain items that are fully described in the Appendix. Please visit the Investor Relations section of the Company’s website at www.masimo.com to access additional informa
Slide 4: Fourth Quarter 2022 Results | Non-GAAP
(In millions; except EPS) Actual Prior Year vs. Prior Revenue $617 $328 88% Healthcare 352 328 7% Non-Healthcare 265 N/A N/A Gross Profit $319 $216 48% Healthcare 217 216 0% Non-Healthcare 102 N/A N/A Gross Margin 51.7% 65.9% -1420 bps Healthcare 61.6% 65.9% -430 bps Non-Healthcare 38.5% N/A N/A Ope
Slide 5: Full Year 2022 Financial Highlights
Consolidated Revenue $2,036 million ($2,293 million on a pro forma basis) Full Year 2022 Financial Highlights(1) (1) Non-GAAP measures shown have been adjusted for certain items that are fully described in the Appendix. Please visit the Investor Relations section of the Company’s website at www.masi
Slide 6: Full Year 2022 Results | Non-GAAP
(In millions; except EPS) Actual Prior Year vs. Prior Revenue $2,036 $1,239 64% Healthcare 1,340 1,239 8% Non-Healthcare 695 N/A N/A Gross Profit $1,123 $816 38% Healthcare 870 816 7% Non-Healthcare 252 N/A N/A Gross Margin 55.1% 65.8% -1070 bps Healthcare 64.9% 65.8% -90 bps Non-Healthcare 36.3% N/
Slide 7: Full Year 2023 Guidance
Consolidated Revenue $2,415 to $2,460 million Full Year 2023 Guidance as of February 28, 2023(1) (1) Non-GAAP measures shown have been adjusted for certain items that are fully described in the Appendix. Please visit the Investor Relations section of the Company’s website at www.masimo.com to access
Slide 8: Full Year 2023 Guidance | Non-GAAP
Guidance vs. Prior Year (In millions; except EPS) Low High Prior Year Low High Revenue $2,415 $2,460 $2,036 19% 21% Healthcare 1,450 1,465 1,340 8% 9% Non-Healthcare 965 995 695 39% 43% Gross Profit $1,312 $1,338 $1,123 17% 19% Healthcare 921 932 870 6% 7% Non-Healthcare 391 407 252 55% 61% Gross Ma
Slide 9: 2023 Guidance Summary
2023 Guidance Summary as of February 28, 2023(1) (1) Non-GAAP measures shown have been adjusted for certain items that are fully described in the Appendix. Please visit the Investor Relations section of the Company’s website at www.masimo.com to access additional information related to our Non-GAAP
Slide 10: Appendices: GAAP to Non-GAAP Reconciliations
Appendices GAAP to Non-GAAP Reconciliations
Slide 11: Income Statement
Consolidated Income Statement (1) Totals may not foot due to rounding. Annual reported amounts may vary from amounts previously reported due to rounding conventions. (2) 2023 Guidance provided on February 28, 2023. (Unaudited; in millions, except per share data) (1) Q1 2022 Q2 2022 Q3 2022 Q4 2022 F
Slide 12: Income Statement
Consolidated Income Statement (1) Totals may not foot due to rounding. Annual reported amounts may vary from amounts previously reported due to rounding conventions. (2) 2023 Guidance provided on February 28, 2023. (Unaudited; in millions, except per share data) (1) Q1 2022 Q2 2022 Q3 2022 Q4 2022 F
Slide 13: Revenue
Revenue (1) Totals may not foot due to rounding. Annual reported amounts may vary from amounts previously reported due to rounding conventions. (2) 2023 Guidance provided on February 28, 2023. (3) Constant currency adjustments are intended to reflect current year revenue at prior year foreign exchan
Slide 14: Segment Reporting
Segment Reporting (1) Totals may not foot due to rounding. Annual reported amounts may vary from amounts previously reported due to rounding conventions. (2) 2023 Guidance provided on February 28, 2023. (Unaudited; in millions) (1) Q1 2023 Guidance (2) FY 2023 Guidance (2) Q1 2022 Q2 2022 Q3 2022 Q4